CTLA4 and cancer: Over the past decade, immune checkpoint inhibitors (ICIs), including antibodies against the programmed death 1 (PD-1) receptor, its ligand (PD-L1), and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), have become a mainstay of treatment against cancer.